Mr. Shaun Flanagan:

As regards fampridine, that has been a difficult assessment process. We have gone back and renegotiated with the company. We have also re-engaged with clinical specialists. We are working to try to agree a protocol that might allow us to extend reimbursement. The particular difficulty with fampridine is that about one third of patients get a good response, one third get a partial response and one third get no response. Clearly, if one could be certain that one was only paying at a reasonable price for the people who get a very good response, one would be more eager to reimburse. We are trying to work towards that outcome. We are hopeful of progress on that in the near future.

The last question concerned the healthwave type of scenario.